Linezolid Articles
Pfizer agrees $55 million settlement for off-label promotion of Protonix by Wyeth; strikes deal over Zyvox and Lyrica
13 December 2012
Vancomycin continues to dominate MRSA treatment with up to 76% of US specialists using the drug; Study
25 May 2011
US Court imposes record fine and forfeiture of $1.3 billion for Pfizer unit’s fraudulent marketing of Bextra
19 October 2009
Novartis to pay up to $485 million for Paratek’s IV antibiotic
12 October 2009
Analysts expect profit for Theravance in 2012
2 March 2009
Strong Ph III data for Arpida's iclaprim
3 November 2008
Pfizer's Zyvox could be "ray of hope" for drug-resistant TB
20 October 2008
Tentative FDA appro for Mylan's generic Zyvox
14 July 2008
Positive Ph III data for Forest's MRSA drug
30 June 2008
Pfizer
23 July 2007
Need for drugs to tackle "superbugs"
18 June 2007
Pfizer's 1st-qtr profits tumble 17.5%
30 April 2007
UK MHRA orders stop on Pfizer ad
19 March 2007
Pfizer's Zyvox cleared for additional use
4 August 2003
New data on Zyvox
5 August 2002
MRSA study in favor of Pharmacia's Zyvox
24 June 2002
Pharmacia fights
25 March 2002
Pharmacia 4th-qtr profits take a dip but Celebrex still selling well
11 February 2002
Glenmark pretax profits rise 54%
4 February 2002
Pharmacia's product pipeline; what's in store after Celebrex?
29 November 2001
Aventis to sell Synercid in Japan
15 November 2001
Pharmacia earnings up 20%, sales rise 5%
25 July 2001
Recent Japanese drug approvals for multinationals
24 April 2001
Pharmacia downplays Zyvox resistance
17 April 2001
Pharmacia fourth-quarter earnings jump 32%, driven by Celebrex sales
13 February 2001
Pharmacia's Zyvox launched in UK
8 February 2001
Healthy harvest of New Chemical Entities in 2000
2 January 2001
Indian firms to launch new drugs this fiscal year
29 August 2000
Pharmacia plans for Japanese market
21 July 2000
Pharmacia wins FDA OK for Zyvox
19 April 2000
P&U files for European approval of linezolid
16 December 1999
P&U continues turnaround, looking for 1999 double-digit growth
29 October 1999
P&U's Aromasin approved by FDA
28 October 1999
P&U to file NDA for linezolid by year-end, new Phase III data
29 September 1999
P&U's linezolid, new data revealed
17 August 1999
New product line up at Pharmacia & Upjohn
16 April 1999
P&U pursues novel antibiotics in $30m deal
7 April 1999
Linezolid shows promise
29 March 1999
Pharmacia & Upjohn Posts Strong Growth For 3rd Qtr
3 November 1998
New Antibacterials Showcased At ICAAC
14 October 1998
CSFB Initiates Coverage Of Pharmacia & Upjohn
12 January 1998
1998 - A "Critical" Year For P&U, Says CEO
3 December 1997
Will New Wave Of Antibiotics Fight Resistance?
23 October 1997
Lack Of New Drugs To Fight Resistant Infections
9 September 1996
Showing 1-61 of 61 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
